Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial
Mattijs Out, Ida Miedema, Harriet Jager-Wittenaar, Cees van der Schans, Wim Krijnen, Philippe Lehert, Coen Stehouwer, Adriaan Kooy
Diabetes, Obesity and Metabolism | WILEY | Published : 2018
The Hyperinsulinaemia: the Outcome of its Metabolic Effects (HOME) trial (ClinicalTrials.gov identifier NCT00375388) was supported by grants from Altana, Lifescan, Merck Sante, Merck Sharp & Dohme and Novo Nordisk. The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.